Standard Biotools earnings release, May 5, 2026

Standard Biotools Inc. (LAB) · Form 8-K, Item 2.02 · Filed · SEC filing

Standard BioTools Reports First Quarter 2026 Financial Results

BOSTON, Mass., May 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.

Recent Highlights:

• First quarter 2026 revenue of $21.1 million

• 54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026

• $524 million in cash & investments as of March 31, 2026, excluding $25 million earnout received after quarter end, to fuel inorganic growth strategy

“We delivered a strong start to 2026, with first quarter performance coming in above expectations,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are operating our base business with consistency, delivering year-over-year top-line growth, and our cost savings initiatives are taking hold with a 78% improvement in adjusted EBITDA to a loss of $3.1 million in the quarter, reinforcing our path to profitability in 2026.”

Dr. Egholm continued, “With the sale of SomaLogic to Illumina complete, we are fully focused on strategic capital deployment to transform the business. Our strong balance sheet, with approximately $550 million in cash and investments inclusive of a $25 million earnout received after quarter end, provides substantial flexibility to pursue attractive opportunities and create shareholder value.”

Financial Results Table: Continuing Operations

First Quarter 2026 Financial Results: Continuing Operations

• Revenue was $21.1 million in the first quarter of 2026, up 5% year-over-year.

• Consumables revenue was $11.0 million in the first quarter of 2026, up 35% year-over-year. Greater consumables revenue in the quarter reflected growth across all product categories, primarily driven by microfluidics.

• Instruments revenue was $4.5 million in the first quarter of 2026, down 33% year-over-year. Instrument revenue in the quarter, compared against particularly strong prior year results, remained impacted by capital-constrained end-markets.

• Services revenue, which is predominantly Field Services, was $5.7 million in the first quarter of 2026, up 5% year-over-year.

• Gross margins in the first quarter of 2026 were approximately 53.5%, versus 54.6% in the first quarter of 2025; and non-GAAP gross margins in the first quarter of 2026 were approximately 57.7%, versus 57.1% in the first quarter of 2025. Gross margins and non-GAAP gross margins were driven by volume and product mix.

• Operating expenses in the first quarter of 2026 were $23.8 million, a decrease of $14.2 million, or down 37%, compared to the first quarter of 2025. Operating expenses included $3.1 million in restructuring and related charges. Non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were $15.3 million in the first quarter of 2026, a decrease of $10.3 million, or down 40%, compared to the first quarter of 2025. The decrease in operating expenses was largely due to previously announced restructuring actions.

• Net loss for the first quarter of 2026 was $14.6 million, compared to a net loss of $23.4 million in the first quarter of 2025, representing a change of $8.7 million or 37%. Adjusted EBITDA for the first quarter of 2026 was a loss of $3.1 million, versus an adjusted EBITDA loss of $14.1 million in the first quarter of 2025, an improvement of $11.0 million, or 78%.

Full Year 2026 Revenue Outlook

For fiscal year 2026, the Company continues to expect revenue in the range of $80 million to $85 million.

Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP financial measures are presented in the accompanying tables of this release.

Financial statements

Income Statement

Financial Results Table: Continuing Operations (Unaudited, in millions, except percentages)

As Reported – Three Months Ended – March 31, 2026As Reported – Three Months Ended – March 31, 2025
Revenue21.120.2
Gross margin53.554.6
Non-GAAP gross margin57.757.1
Operating expenses23.838
Non-GAAP operating expenses15.325.6
Operating loss-12.5-27
Net loss from continuing operations-14.6-23.4
Adjusted EBITDA-3.1-14.1
Cash, cash equivalents, restricted cash, and liquid investments523.6260.7

Income Statement

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Product revenue15,45414,781
Revenue:Services and other revenue5,6925,441
Revenue:Total revenue21,14620,222
Cost of revenue:Cost of product revenue7,7066,431
Cost of revenue:Cost of services and other revenue2,1322,742
Cost of revenue:Total cost of revenue9,8389,173
Cost of revenue:Gross profit11,30811,049
Operating expenses:Research and development2,1175,440
Operating expenses:Selling, general and administrative18,60729,824
Operating expenses:Restructuring and related charges3,0801,552
Operating expenses:Transaction and integration expenses1,203
Operating expenses:Total operating expenses23,80438,019
Operating expenses:Loss from operations-12,496-26,970
Operating expenses:Interest income, net3,5112,914
Operating expenses:Other (expense) income, net-5,630567
Operating expenses:Loss before income taxes-14,615-23,489
Operating expenses:Income tax (expense) benefit-11119
Operating expenses:Net loss from continuing operations-14,626-23,370
Discontinued operations:Income (loss) from discontinued operations, net of tax141,694-2,663
Discontinued operations:Net income (loss)127,068-26,033
Discontinued operations:Net loss per share from continuing operations-0.04-0.06
Discontinued operations:Net income (loss) per share from discontinued operations0.37-0.01
Discontinued operations:Net income (loss) per share0.33-0.07
Discontinued operations:Shares used in computing net income (loss) per share attributable to common stockholders388,202378,228

Income Statement

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Product revenue:Instruments4,4706,646
Product revenue:Consumables10,9848,135
Product revenue:Total product revenue15,45414,781
Product revenue:Services and other revenue5,6925,441
Product revenue:Total revenue21,14620,222

Income Statement

Three Months Ended March 31, — ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Gross profit11,30811,049
Depreciation and amortization346263
Stock-based compensation expense541242
Non-GAAP gross profit12,19511,554
Gross margin percentage53.5%54.6
Depreciation and amortization1.6%1.3
Stock-based compensation expense2.6%1.2
Non-GAAP gross margin percentage57.7%57.1

Balance Sheet

March 31, 2026 — (Unaudited) (in thousands)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents265,772120,863
Current assets:Short-term investments189,40466,712
Current assets:Accounts receivable, net16,63713,431
Current assets:Inventory18,59419,981
Current assets:Prepaid expenses and other current assets6,0464,871
Current assets:Contingent consideration receivable25,000
Current assets:Current assets held for sale228,406
Current assets:Total current assets521,453454,264
Current assets:Property and equipment, net17,10319,275
Current assets:Operating lease right-of-use asset, net25,54526,732
Current assets:Other non-current assets3,3863,154
Current assets:Long-term investments71,35725,701
Current assets:Deferred tax asset, non-current27038,628
Current assets:Total assets639,114567,754
Current liabilities:Accounts payable8,0075,407
Current liabilities:Accrued liabilities15,68429,783
Current liabilities:Operating lease liabilities, current5,5405,490
Current liabilities:Deferred revenue, current9,98138,949
Current liabilities:Deferred grant income, current2,9913,046
Current liabilities:Current liabilities held for sale25,633
Current liabilities:Total current liabilities42,203108,308
Current liabilities:Convertible notes, non-current299299
Current liabilities:Deferred tax liability823810
Current liabilities:Operating lease liabilities, non-current23,65225,038
Current liabilities:Deferred revenue, non-current3,0133,503
Current liabilities:Deferred grant income, non-current3,5574,290
Current liabilities:Other non-current liabilities4,4441,215
Current liabilities:Total liabilities77,991143,463
Current liabilities:Total stockholders’ equity561,123424,291
Current liabilities:Total liabilities and stockholders’ equity639,114567,754

Cash Flow

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Operating activitiesNet income (loss)127,068-26,033
Operating activitiesGain on sale of business-172,289
Operating activitiesStock-based compensation expense8,8249,009
Operating activitiesAmortization of acquired intangible assets898
Operating activitiesDepreciation and amortization1,4083,273
Full release

Forward-Looking Statements... (truncated)cluding the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; risks that the anticipated benefits and synergies resulting from prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; existing and potential future NIH funding pressures; the effect from existing and potential future U.S. export controls and tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K, for the year ended December 31, 2025, filed with the SEC on March 16, 2026, the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2026, to be filed with the SEC, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools, Inc. (Nasdaq: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact: ir@standardbio.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Standard Biotools earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.